Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 May 29;92(12):e00285-18.
doi: 10.1128/JVI.00285-18. Print 2018 Jun 15.

Effect of Short-Term Antiretroviral Therapy Interruption on Levels of Integrated HIV DNA

Affiliations

Effect of Short-Term Antiretroviral Therapy Interruption on Levels of Integrated HIV DNA

Zachary Strongin et al. J Virol. .

Abstract

Analytic treatment interruption (ATI) studies are required to evaluate strategies aimed at achieving ART-free HIV remission, but the impact of ATI on the viral reservoir remains unclear. We validated a DNA size selection-based assay for measuring levels of integrated HIV DNA and applied it to assess the effects of short-term ATI on the HIV reservoir. Samples from participants from four AIDS Clinical Trials Group ATI studies were assayed for integrated HIV DNA levels. Cryopreserved peripheral blood mononuclear cells (PBMCs) were obtained for 12 participants with available samples pre-ATI and approximately 6 months after ART resumption. Four participants also had samples available during the ATI. The median duration of ATI was 12 weeks. Validation of the HIV integrated DNA size-exclusion (HIDE) assay was performed using samples spiked with unintegrated HIV DNA, HIV-infected cell lines, and participant PBMCs. The HIDE assay eliminated 99% of unintegrated HIV DNA species and strongly correlated with the established Alu-gag assay. For the majority of individuals, integrated DNA levels increased during ATI and subsequently declined upon ART resumption. There was no significant difference in the levels of integrated HIV DNA between the pre- and post-ATI time points, with a median ratio of post- to pre-ATI HIV DNA levels of 0.95. Using a new integrated HIV DNA assay, we found minimal change in the levels of integrated HIV DNA in participants who underwent an ATI, followed by 6 months of ART. This suggests that short-term ATI can be conducted without a significant impact on the levels of integrated proviral DNA in the peripheral blood.IMPORTANCE Interventions aimed at achieving sustained antiretroviral therapy (ART)-free HIV remission require treatment interruption trials to assess their efficacy. However, these trials are accompanied by safety concerns related to the expansion of the viral reservoir. We validated an assay that uses an automated DNA size-selection platform for quantifying levels of integrated HIV DNA and is less sample- and labor-intensive than current assays. Using stored samples from AIDS Clinical Trials Group studies, we found that short-term ART discontinuation had minimal impact on integrated HIV DNA levels after ART resumption, providing reassurance about the reservoir effects of short-term treatment interruption trials.

Keywords: HIV; assay; integrated DNA; reservoir; treatment interruption.

PubMed Disclaimer

Figures

FIG 1
FIG 1
Viral loads and CD4+ counts. Blue lines depict viral loads, and red lines depict CD4+ cell counts. The ATI period is shaded gray, and on-ART data are shown as white.
FIG 2
FIG 2
HIDE assay validation. (a) DNA recovery percentage for each sample after 20-kb size selection on the BluePippin platform. (b) HIV DNA levels of uninfected DNA spiked with linear or circular HIV DNA before and after genomic DNA size selection. (c) HIV DNA levels in three cell lines (J-Lat, HIV-infected CEM, and two dilutions of 8E5) containing integrated, replication-deficient HIV provirus before and after size selection by HIDE assay. (d) Levels of total and size-selected HIV DNA in a representative participant (PID 4) at pre-ATI, during ATI, and post-ATI time points. (e) Correlation between integrated HIV DNA levels measured by the HIDE assay and by the Alu-gag assay for cell lines (triangles) and participant samples (circles).
FIG 3
FIG 3
Treatment interruption had minimal effect on levels of integrated HIV DNA in PBMCs. (a) Levels of integrated HIV DNA pre-ATI, during treatment interruption, and post-ATI in four participants. Participant numbers are written next to the corresponding pre-ATI data point. (b) Pre- and post-ATI levels of integrated HIV DNA for 12 participants. For samples that are below the LOD, the LOD for that sample is used (open circle). (c) Ratio of post-ATI to pre-ATI levels of integrated HIV DNA. An open circle represents whether either the pre- or post-ATI time point was below the LOD. The line represents the median value.

Similar articles

Cited by

References

    1. Chun TW, Fauci AS. 1999. Latent reservoirs of HIV: obstacles to the eradication of virus. Proc Natl Acad Sci U S A 96:10958–10961. doi:10.1073/pnas.96.20.10958. - DOI - PMC - PubMed
    1. Finzi D, Blankson J, Siliciano JD, Margolick JB, Chadwick K, Pierson T, Smith K, Lisziewicz J, Lori F, Flexner C, Quinn TC, Chaisson RE, Rosenberg E, Walker B, Gange S, Gallant J, Siliciano RF. 1999. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med 5:512–517. doi:10.1038/8394. - DOI - PubMed
    1. Besson GJ, Lalama CM, Bosch RJ, Gandhi RT, Bedison MA, Aga E, Riddler SA, McMahon DK, Hong F, Mellors JW. 2014. HIV-1 DNA decay dynamics in blood during more than a decade of suppressive antiretroviral therapy. Clin Infect Dis 59:1312–1321. doi:10.1093/cid/ciu585. - DOI - PMC - PubMed
    1. Gandhi RT, McMahon DK, Bosch RJ, Lalama CM, Cyktor JC, Macatangay BJ, Rinaldo CR, Riddler SA, Hogg E, Godfrey C, Collier AC, Eron JJ, Mellors JW. 2017. Levels of HIV-1 persistence on antiretroviral therapy are not associated with markers of inflammation or activation. PLoS Pathog 13:1–21. doi:10.1371/journal.ppat.1006285. - DOI - PMC - PubMed
    1. Li JZ, Etemad B, Ahmed H, Aga E, Bosch RJ, Mellors JW, Kuritzkes DR, Lederman MM, Para M, Gandhi RT. 2016. The size of the expressed HIV reservoir predicts timing of viral rebound after treatment interruption. AIDS 30:343–353. doi:10.1097/QAD.0000000000000971. - DOI - PMC - PubMed

Publication types